PDE1 inhibition modulates Ca_v1.2 channel to stimulate cardiomyocyte contraction

Short Title: PDE1 Regulation of Contraction via Ca_v1.2

Grace K Muller¹, Joy Song¹, Vivek Jani¹, Yuejin Wu¹,
Mark E Anderson¹,²,³, David A Kass¹,³,⁴

¹ Division of Cardiology
² Department of Physiology
³ Graduate Program in Cellular and Molecular Medicine
⁴ Departments of Pharmacology and Molecular Sciences and Biomedical Engineering
The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

Corresponding Author
David A Kass, MD
Virginia Professor of Cardiology
Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD 21205
dkass@jhmi.edu
FAX) 410-367-2225
TEL) 410-955-7153

Article type: Research Article
Word Count: 7860
ABSTRACT

Rationale. Cyclic adenosine monophosphate (cAMP) activation of protein kinase A (PKA) stimulates excitation-contraction coupling, increasing cardiac contractility. This is clinically leveraged by beta-adrenergic stimulation (β-ARs) or phosphodiesterase-3 inhibition (PDE3i), though both approaches are limited by arrhythmia and chronic myocardial toxicity. Phosphodiesterase-1 inhibition (PDE1i) also augments cAMP and was recently shown in rabbit cardiomyocytes to augment contraction independent of β-AR stimulation or blockade, and with less intracellular calcium rise than β-ARs or PDE3i. Early testing of PDE1 inhibition in humans with neuro-degenerative disease and dilated heart failure has commenced. Yet, the molecular mechanisms for PDE1i inotropic effects remain largely unknown.

Objective. Define the mechanism(s) whereby PDE1i increases contractility.

Methods and Results. Primary guinea pig myocytes which express the cAMP-hydrolyzing PDE1C isoform found in larger mammals and humans were studied. The potent, selective PDE1i (ITI-214) did not alter cell shortening or Ca\(^{2+}\) transients under resting conditions whereas both increased with β-ARs or PDE3i. However, PDE1i enhanced shortening with less Ca\(^{2+}\) rise in a PKA-dependent manner when combined with low-dose adenylate cyclase stimulation (Forskolin). Unlike PDE3i, PDE1i did not augment β-AR responses. Whereas β-ARs reduced myofilament Ca\(^{2+}\) sensitivity and increased sarcoplasmic reticular Ca\(^{2+}\) content in conjunction with greater phosphorylation of troponin I, myosin binding protein C, and phospholamban, PDE1i did none of this. However, PDE1i increased Ca\(_{\nu1.2}\) channel conductance similar to PDE3i.
in a PKA-dependent manner. Myocyte shortening and peak Ca\textsuperscript{2+} transients were more sensitive to Ca\textsubscript{v}1.2 blockade with nitrendipine combined with PDE1i versus PDE3i. Lastly, PDE1i was found to be far less arrhythmogenic than PDE3i.

**Conclusions.** PDE1i enhances contractility by a PKA-dependent increase in Ca\textsubscript{v}1.2 conductance without concomitant myofilament desensitization. The result is less rise in intracellular Ca\textsuperscript{2+} and arrhythmia compared to β-ARs and/or PDE3i. PDE1i could be a novel positive inotrope for failing hearts without the toxicities of β-ARs and PDE3i.

**Key Words:** myocyte, contractility, inotropy, phosphodiesterase-1, L-type calcium channel, excitation-contraction coupling, arrhythmia

**Non-standard Abbreviations and Acronyms:**

- β-ARs (β adrenergic receptor stimulation)
- PDE1i (phosphodiesterase type 1 inhibition)
- PDE3i (phosphodiesterase type 3 inhibition)
- PLN – phospholamban
- SR – sarcoplasmic reticulum
- TnI – troponin I
- MyBPC – myosin binding protein C
INTRODUCTION

Heart failure with depressed systolic function is a leading cause of morbidity and mortality and currently affects tens of millions of patients worldwide with a rising prevalence\(^1\). Current drug treatments focus on reducing volume overload with diuretics and blocking β-adrenergic receptor (β-AR) and angiotensin stimulation. Methods to increase contractility have historically mimicked β-AR agonism to increase cyclic adenosine monophosphate (cAMP), which activates protein kinase A, though new methods to enhance sarcomere function directly are under development\(^2\). At present the most widely used therapeutics are the β-AR agonist dobutamine and phosphodiesterase type 3 (PDE3) inhibitor milrinone, the latter enhancing cAMP signaling by suppressing its hydrolysis. The inotropic effects from either are less potent in failing hearts as β-adrenergic receptor signaling and adenylyl cyclase activity are downregulated\(^3\). Their influence is further curtailed in many patients by the therapeutic use of β-AR blockade\(^4\). Importantly, both approaches raise intra-cellular calcium and are pro-arrhythmic, factors which have constrained their use to acute indications\(^5-7\). Safe and effective alternatives amenable to chronic therapy are lacking.

PDE1 is a dual cyclic nucleotide phosphodiesterase that is highly expressed in the mammalian heart. It is unique among PDEs because it requires calcium/calmodulin for activation. PDE1 is expressed as one of three isoforms, with PDE1C being most prominently expressed in human and other larger mammalian hearts. This isoform exhibits balanced selectivity for cAMP and cGMP, whereas isoform 1A, which is primarily expressed in rat and mouse heart, favors cGMP hydrolysis\(^8,9\). In 2018, we
first reported that a pan-isoform inhibitor of PDE1 (ITI-214) increases contractility and reduces vascular resistance in conscious dogs with normal or failing hearts, and in intact rabbits. Our study further revealed that such effects were independent of β-AR stimulation (β-ARs) or blockade and changes in heart rate. Moreover, PDE1 inhibition (PDE1i) regulated cAMP differently than β-ARs or PDE3 inhibition (PDE3i), increasing myocyte contraction but with less intracellular calcium rise. These results have since led to a Phase Ib-IIa placebo-controlled study of ITI-214 in humans with dilated heart failure (NCT03387215). Preliminary results show positive inotropic and vasodilator effects much as found in dogs and rabbits.

The intracellular mechanisms whereby PDE1i augments contractility remain unknown. PKA activation by β-AR stimulation leads to phosphorylation of the regulatory protein Rad to increase Ca\textsubscript{v}1.2 (L-type calcium channel) conductance. Concomitant PKA phosphorylation of phospholamban (PLN) disinhibits the sarcoplasmic reticulum (SR) Ca\textsuperscript{2+} ATPase (SERCA) to increase SR calcium uptake and calcium-induced calcium release. PDE3A localizes to the SR where it regulates cAMP-PKA stimulation, so its inhibition can further augment SERCA2a activity. Collectively, these changes increase peak intracellular calcium transients and hasten their decline, improving contraction and relaxation. At the sarcomere, PKA phosphorylates troponin I (TnI) that desensitizes myofilaments to calcium and enhances relaxation, and myosin binding protein C (MyBP-C) which accelerates activation kinetics and increases β-ARs mediated contraction.
Given that calcium transients are less altered by PDE1i, we hypothesized that intracellular PKA modulation and its consequences differ between β-ARs or PDE3i vs PDE1i. The current study tested this using guinea pig myocytes that also express the PDE1C isoform as in rabbits and humans. We find that the primary impact of PDE1i is to increase Ca\textsubscript{v}1.2 conductance without impacting PLN, TnI, or MyBP-C phosphorylation and associated with this, no change in SR calcium load or myofilament calcium sensitivity. The result is enhanced inotropy with less rise in intracellular calcium concentration and pro-arrhythmia than is observed with β-ARs and/or PDE3i.
METHODS

Reagents

The following reagents were used in the study: PDE1i - ITI-214 (provided under research agreement with Intra-Cellular Therapies, Inc, NY), cilostamide, forskolin and rolipram (Tocris, Minneapolis, MN), DMSO, Rp-cAMPS, caffeine, nitrendipine, verapamil (Millipore Sigma, Burlington, MA), and Rp-8-CPT-cAMPS (Cayman Chemical, Ann Arbor, MI). The following antibodies were used: PDE1A (1:1000, Sc-50480, H-105, Santa Cruz Biotechnology, Dallas, TX), PDE1C (1:5000, Ab14602, Abcam, Cambridge, MA), GAPDH (1:2000, 5174, Cell-Signaling, Danvers, MA), phospho-Ser24/25 troponin I (1:1000, ThermoFisher Scientific) and total troponin I (1:1000, ThermoFisher Scientific), phospho-Ser273, -Ser282, -Ser302 and total MyBP-C (1:2000, 1:4000, 1:4000, 1:2000, respectively, gifts from Dr. Sakthivel Sadayappan, University of Cincinnati), phospho-Ser16 phospholamban (1:2000, Badrilla, Leeds, UK), total phospholamban (1:3000, ThermoFisher Scientific, Grand Island, NY). To obtain single band detection with PDE1C Ab, we used 0.1% KPL (SeraCare, Milford, MA) as the blocking buffer. For all other immunoblots, we used Odyssey Blocking Buffer (Li-Cor, Lincoln, NE) 1:1 in TBST.

Animals

Guinea pigs (N=57, males, 350-500 g) were used in this study. All animal study procedures were performed in accordance with the Guide to the Care and Use of Laboratory Animals and approved by the Johns Hopkins University Institutional Animal Care and Use Committee.
**Myocyte cell isolation**

The protocol used for guinea pig myocyte isolation is described in detail elsewhere \(^{19}\). Briefly, guinea pigs were anesthetized with pentobarbital, and hearts rapidly removed via thoracotomy. The aorta was cannulated on a Langendorff apparatus fitted with a heating jacket circulating water at 37 °C, and retrograde-perfused for 5 minutes at 8 ml/min with Tyrode’s solution. The perfusate was then switched to Tyrode’s solution containing collagen type 2 (Worthington, Columbus, OH) and protease type 14 (Sigma-Aldrich, St. Louis, MO) for 7-9 minutes. The solution was switched to a modified Kraft-Bruhe (KB) buffer for 5 minutes, before hearts were minced and filtered (200 µm) to yield single cells. Myocytes were then rested in modified KB buffer \(^{20}\) for one hour before being placed in supplemented M199 ACCIT medium \(^{21}\). Cells were maintained at room temperature and studied over 7 hours.

**Sarcomere shortening and Ca\(^{2+}\) transients**

Changes in cell sarcomere shortening and Ca\(^{2+}\) transients were measured using a customized IonOptix system previously described \(^{8}\). All recordings were performed at 37° C, with pacing stimulation at 1 Hz. Cells were loaded using 1 µM Fura-2 for 15 minutes and then washed for at least 20 minutes. Baseline recordings were made in Tyrode’s buffer with 0.1% DMSO. Cells were subsequently stimulated with various agents as described in results. Three baseline parameters were considered for the two types of measurements (pre-stimulation, peak percent change after stimulation, and time to return to 50% baseline). Cells falling within 2 standard deviations of the mean
value were included in group analysis. To determine the role of PKA in PDE1i or PDE3i mediated response, cells were pre-incubated with 100 µM Rp-8-CPT-cAMPS for 35-45 minutes before being studied. To assess SR Ca²⁺ content, caffeine-induced SR Ca²⁺ release was performed as previously described. For this assay, stable responses to forskolin+ITI-214 or Iso, or DMSO in normal Tyrode’s were recorded for one minute prior to stopping pacing, and caffeine (10 mM) introduced via a needle placed adjacent to the cell. The peak Ca²⁺ transient was quantified.

**Myofilament force-pCa relationship in skinned myocytes**

Myocytes were incubated in 0.3% Triton X-100 in isolation buffer with protease inhibitor (Sigma-Aldrich) and phosphatase inhibitor (PhosSTOP, Roche, Indianapolis, IN) for 20 minutes at 10°C as described earlier. After washing in isolation buffer, cells were attached with UV-activated adhesive (Norland Products, Cranbury, NJ) to a force transducer-length controller (Aurora Scientific, Aurora, Canada). Sarcomere length was adjusted to 2.1 µm with micromanipulators (Siskiyou Corporation, Grants Pass, OR) as measured by digital 2D fast Fourier transform of images (IPX-VGA210, Imperx, Boca Raton, FL). Tension was equal to force divided by myocyte cross sectional area. Active tension-Ca²⁺ relationships were generated by varying Ca²⁺ concentration from 0 to 46.8 µmol/L. Tension-log[Ca²⁺] relations were fit to the Hill equation to obtain maximal tension (Tₘₐₓ), Ca²⁺ sensitivity (EC₅₀), and Hill coefficient. Tension-pCa relationships were normalized to Tₘₐₓ.
L-type Ca\(^{2+}\) current density recordings

\(\text{Ca}v1.2\) current (\(I_{\text{Ca}}\)) was measured with whole-cell patch clamp at 34±1 °C, as reported\(^{26}\). \(I_{\text{Ca}}\) was confirmed by sensitivity to nitrendipine (10 µM). Depolarizing voltage pulses (300 ms in duration) to potentials ranging -70 to 60 mV, in 10 mV steps, were applied from a holding potential of -80 mV. A pre-pulse to -40 mV of 50 ms was applied before each step to inactivate Na\(^{+}\) currents. An example voltage protocol is shown in Fig 4a. The pipette (intracellular) solution consisted of (in mM): 120 CsCl, 10 HEPES, 10 tetraethylammonium (TEA) chloride, 1.0 MgCl\(_2\), 1.0 NaGTP, 5.0 phosphocreatine, 3.0 CaCl\(_2\), 10 EGTA; pH was adjusted to 7.2 with 1.0 N CsOH. For PKA inhibition, Rp-cAMPS (100 µM) was included in the pipette. The bath (extracellular) solution consisted of (in mM): 137 NaCl, 10 HEPES, 10 glucose, 1.8 CaCl\(_2\), 0.5 MgCl\(_2\), and 25 CsCl, with pH adjusted to 7.4 with NaOH.

Western blots

To probe for PLN phosphorylation, guinea pig myocytes were incubated with DMSO or various stimulation drugs all dissolved in Tyrode’s with 1.8 mM Ca\(^{2+}\) and rotated in a cell suspension for five minutes at room temperature. Cells were then quickly spun down, Tyrode’s replaced with lysis buffer (Lysis Buffer, Cell Signaling), and homogenized using beads and mechanical shearing at 30 Hz for 2 min (Retsch, Newtown, PA). The lysates were clarified using centrifugation (2000xg, 10 min) and assayed for protein content (BCA Assay, Thermo-Fisher). For sarcomeric proteins, cells were allowed to settle for three hours on laminin-coated 6-well plates. The M199 ACCIT media was
replaced with identical media without bovine serum albumin (BSA) 30 minutes before the drug incubation. Cells were treated with DMSO or indicated drugs dissolved in the BSA-less media and incubated for 10 minutes at room temperature. Sarcomere fractions were isolated and quantitated as reported before \(^{24}\). Proteins were separated on gel electrophoresis, followed by hybrid wet transfer onto nitrocellulose. 12% gels were used for phospholamban; 4-15% gels were used for PDE1A, PDE1C, GAPDH, troponin I and MyBP-C. Li-Cor Imager was used to scan and quantitate densitometry values.

**Statistical analysis**

Raw data were collated using Excel and analyzed and graphed using Prism 8.0. Figures generally display all the individual data along with median and 25/75% in the form of violin plots, or individual data with mean +/- SEM as bar graphs. Other formats and statistics are noted along with statistical tests used in each of the figure legends.
RESULTS

Effects of PDE1-I on cAMP-stimulated contraction in guinea pig myocytes

PDE1 isoform expression has not been previously reported in guinea pig, so we first assessed and confirmed that PDE1A and PDE1C protein are both robustly expressed (Supplemental Fig 1). This pattern is similar to that reported in rabbit and human\(^8\). Figure 1A-C shows myocyte sarcomere shortening and Ca\(^{2+}\) transients at rest and upon exposure to the β-AR agonist isoproterenol (Iso, 1 nM), PDE3i cilostamide (Cil 1 μM), PDE4i rolipram (Rol, 10 μM), or PDE1i (ITI-214, 1 μM). Both Iso and Cil increased shortening and Ca\(^{2+}\) transients similarly. In contrast, neither Rol nor ITI-214 had any effect. The lack of PDE1i response in guinea pig myocytes is similar to data from rabbit\(^8\). The lack of PDE4i responses similar to results from larger mammalian hearts but while contrasting to mouse or rat for which PDE4 dominates EC coupling\(^27\).

Since inotropic effects from PDE1i require sufficient ambient cAMP that can in turn be modulated\(^28\), we next examined the response to PDE1i and PDE3i in cells pre-treated with the adenylate cyclase stimulator forskolin (Fsk). Based on dose response data (Supplemental Fig 2A), cells were exposed to either 10 or 100 nM Fsk alone or in combination with PDE1i or PDE3i (Figure 1D, 1E). PDE1i significantly augmented shortening but not Ca\(^{2+}\) transients whereas PDE3i increased both at either dose of Fsk pre-stimulation. To test whether inotropic enhancement by PDE1i requires PKA activation, we repeated this study using 10 nM Fsk pre-stimulation in the presence or absence of PKA inhibition (Rp-8-CPT-cAMPS, 100 μM). Consistent with prior data, PKA inhibition alone did not alter baseline sarcomere shortening\(^22\) but slowed relaxation.
kinetics (Supplemental Fig 2C). However, PKA inhibition blocked increased contraction (Figure 1F) and enhanced relaxation (Supplemental Fig 2D) from PDE1i and PDE3i.

Lastly, we examined the effect of PDE1i and PDE3i superimposed on β-AR stimulated shortening and Ca^{2+} transients. Both parameters were further augmented by PDE3i whereas PDE1i did not amplify the changes from β-ARs (Figure 2A, 2B). Taken together, these studies identify differences in myocyte function and calcium responses to PDE1i versus PDE3i, but similar dependence on PKA activation.

**Unlike β-AR stimulation, PDE1-I does not alter myofilament tension -Ca^{2+} relations**

Beta-AR stimulation results in phosphorylation of TnI at Ser^{23/24}, causing a rightward shift of the myocyte tension-Ca^{2+} dependence (myofilament desensitization) without changing maximal tension^{29}. This is characterized by greater Ca^{2+} required for 50% activation (EC_{50}). We speculated that by contrast, PDE1i may not desensitize the myofilaments since it augments shortening at less Ca^{2+} elevation. To test this, myocytes incubated for 5 minutes with DMSO, Iso (50 nM), or Fsk (10 nM) + ITI-214 (1 µM) were placed in skinning solution with phosphatase inhibitors, and mounted on a force-length control apparatus to obtain normalized tension (force/cross sectional area) - Ca^{2+} relations. Stimulation with Iso shifted the curve rightward (desensitization) as expected, increasing EC_{50} from 2.42 to 4.61 (p=0.02). However, PDE1i had no significant impact on the relation and EC_{50} (Figure 3A, 3B). Maximal activated tension and Hill cooperativity were unaltered by either intervention (Table 1).
The lack of altered tension-Ca\(^{2+}\) dependence suggested PKA phosphorylation of myofilament proteins, notably TnI and MyBP-C that occur with \(\beta\)-AR stimulation, would be lacking with PDE1i. Figure 3C and D show example immunoblots and summary data, using the same doses that induced similar physiological stimulation. The data are normalized to the maximal response obtained with Fsk+IBMX (100 µM). TnI phosphorylation with Iso was significantly greater than with Fsk+ITI-214. MyBP-C phosphorylation upon \(\beta\)-AR stimulation is important to enhancing contractility\(^{30}\). As PDE1i did not amplify pre-existing \(\beta\)-AR stimulation, we speculated this too did not occur. Iso phosphorylated MyBP-C Ser\(^{273}\), Ser\(^{282}\), and Ser\(^{302}\); however, this was not observed with Fsk+ITI-214.

**PDE1-I does not increase SR Ca\(^{2+}\) load or phospholamban phosphorylation**

A major source of increased Ca\(^{2+}\) with \(\beta\)-AR is from enhanced SR release coupled to increased SR stores. Since PDE1i augmented contraction with less Ca\(^{2+}\) rise, we speculated these SR changes may not occur. Myocytes were treated with Fsk+ITI-214 or Iso in normal Tyrode’s and then exposed to caffeine (10 µM) to induce SR Ca\(^{2+}\) release. Fig 4A displays example Ca\(^{2+}\) response data for caffeine-induced SR Ca\(^{2+}\) storage analysis\(^{31}\), and Figure 4B, summary data for the peak Ca\(^{2+}\) response reflecting SR Ca\(^{2+}\) load. Iso (1 nM) increased SR Ca\(^{2+}\) storage above vehicle control (DMSO), but Fsk+ITI-214 did not. Iso also shortened the Ca\(^{2+}\) decay constant (0.035 ± 0.0036 s) compared to DMSO (0.12 ± 0.013 s; p<0.0047, Kruskal-Wallis test), and this was unaltered by Fsk+214 (0.11 ± 0.016 s) (Figure 4B).
PKA-mediated PLN phosphorylation at Ser\(^{16}\) plays a major role in enhancing SR Ca\(^{2+}\) uptake; therefore, we further examined if Iso and Fsk+ITI-214 differed with respect to this post-translational modification. Myocytes exposed to Iso (50 nM) showed a rise in Ser\(^{16}\) phosphorylation that was not found with Fsk+ITI-214 (Fig 4C). This was further explored in cells treated with PDE1i or PDE3i alone, or in combination with non-saturating levels of Iso or Fsk (Figure 4D, 4E). In all conditions, PDE3i augmented PLN phosphorylation over the prior baseline significantly more than PDE1i.

**Cav1.2 canal current increases with both PDE1- and PDE3-I**

The lack of myofilament or SR modifications by PDE1i led us to consider the opening of Cav1.2 – the key first step in EC coupling. As recently revealed by the Marx laboratory\(^{11, 12}\), PKA phosphorylates the binding protein Rad to dis-inhibit the channel and increase conductance. In larger mammalian cells such as those from dog, rabbit, and guinea pig, the relative role of Cav1.2 versus SR Ca\(^{2+}\) is 1:2 and near 1:1 in failing hearts\(^{32, 33}\). If PDE1i enhanced this current without inducing myofilament Ca\(^{2+}\) desensitization, it could augment contractility even without an SR component. We determined nitrendipine-sensitive I\(_{CaL}\) current density by voltage clamp protocol and average current density plotted versus depolarizing voltage (Fig 5A). Compared to DMSO, the I-V plot remained unaltered by Fsk or ITI-214 alone. However, combining PDE3i or PDE1i with low-dose Fsk (10 nM) resulted in a marked increase in current density (Fig 5B). Summary data for peak current (Fig 5C) confirmed similar enhancement with either PDE inhibitor. A maximal dose of nitrendipine (10 \(\mu\)M) blocked
the current increase elicited by either of the two PDE inhibitors. To test if this effect was PKA dependent, studies were repeated with the PKA inhibitor Rp-cAMP (100 µM) in the recording electrode to dialyze the inhibitor into the cell. PKA inhibition blocked increased current from PDE1i and PDE3i +Fsk (Fig 5D).

Given Fsk+PDE1i augmented Ca\textsubscript{v}1.2 current similarly as Fsk+PDE3i but without the latter’s engagement of the SR, we postulated that Fsk+PDE1i would be more sensitive to nitrendipine. Doses of nitrendipine that depressed but did not prevent myocyte shortening were determined in a range of 0.01–3 µM (Supplemental Fig 3A). Cells were treated with either DMSO, Fsk+PDE1i, or PDE3i (Fig 6A and B) with increasing nitrendipine dose. Fsk+PDE1/3i-stimulated shortening and peak Ca\textsuperscript{2+} transients with either inhibitor exhibited a nitrendipine dose-dependent decline. However, this sensitivity was greater in cells stimulated with Fsk+PDE1i as determined by a significantly steeper dose-response (Fig 6C). This was statistically significant as determined in log-transformed relations by analysis of covariance (Fig 6C and D).

**PDE1i is less arrhythmogenic than PDE3i**

Increased SR Ca\textsuperscript{2+} load and/or release is viewed as a potential cause for arrhythmia and attributed to pro-arrhythmia with both β-AR and PDE3i. As PDE1i did not alter SR Ca\textsuperscript{2+} load (unlike PDE3i), we hypothesized it may also be less arrhythmogenic despite increasing Ca\textsubscript{v}1.2 Ca\textsuperscript{2+} conductance. Myocytes treated with PDE1i or PDE3i in the presence of 0, 10, or 100 nM Fsk were examined for rhythm stability (fixed amplitude and rate under paced conditions) or arrhythmia (both
parameters showing variability despite pacing). Figure 7A shows example tracings, and Figure 7B shows summary data for the relative percent of stable versus arrhythmic cells. PDE3i elicited more arrhythmia at lower Fsk doses than did PDE1i. This was most apparent without Fsk (81% vs 5%, p<0.0001) but persisted despite Fsk co-stimulation.

**Discussion**

This study reveals the mechanisms of inotropic modulation in cardiac myocytes from guinea pig that express PDE1C by a broad PDE1i and contrasts the findings to those from PDE3i. As summarized in Figure 8, we find PDE1i augments contractility in a PKA dependent manner by increasing Ca\textsubscript{v}1.2 current density; however, in contrast to β-ARs, PDE1i does not desensitize the myofilaments to Ca\textsuperscript{2+}. Thus, while we find no increase in SR Ca\textsuperscript{2+} load or PLN phosphorylation, contraction still increases with less total intracellular Ca\textsuperscript{2+} rise as compared to β-ARs or PDE3i. This profile is further supported by greater sensitivity of PDE1i positive inotropy to Ca\textsubscript{v}1.2 blockade. An important correlate is less arrhythmogenicity than observed with PDE3i. These findings deepen our understanding of PDE1 regulation in myocytes and have translational significance as the first clinical trial of a PDE1i, ITI-214, in heart failure patients has found it safe and to enhance contraction\textsuperscript{10}.

**PDE modulators of myocyte contractility**

Acute augmentation of cardiac contractility is primarily coupled to pathways that activate cAMP-PKA signaling. This is intrinsic to β-AR stimulation and other G-protein
coupled receptors such as sub-types of adenosine receptors and glucagon receptors \(^{34}\).

As cAMP itself is the same molecule throughout the cell its signaling requires exquisite local control. This is provided in part by specific cAMP-hydrolyzing PDEs \(^{35}\). In larger mammalian hearts, PDE3 plays a dominant role, whereas PDE4 is more influential in mouse and rat. Until recently, the role of PDE1 in larger mammalian myocytes and hearts was unknown. PDE3 binds cAMP in the nM range \(^{36}\) whereas PDEs 1 and 4 operate at \(\mu\)M ranges \(^9,37\). As intracellular cAMP concentration is \(\sim 1\ \mu\)M \(^{38}\), PDE3 inhibitors are expected to have more impact under resting conditions even in isolated myocytes. By contrast, although PDE1i \textit{in vivo} augments contractility, in isolated cells devoid of adrenergic tone, cAMP must first be elevated to observe inotropy as show here in guinea pig and previously in mouse and rabbit \(^8,39\).

\textit{Evidence for distinct PDE1 vs PDE3 localization}

Beyond their relative affinity for cAMP, differential regulation by spatially compartmentalized PDEs control local cAMP-PKA signaling \(^40\). PDE3 is found at the plasma membrane \(^41\) and also at the SR where it controls local Ca\(^{2+}\) uptake \(^15\). PDE1 also localizes to the plasma membrane and displays immunofluorescence staining along Z- and M-lines in human myocytes \(^42\). However, PDE1 accounts for only 14\% of microsomal PDE activity against cAMP as compared to 78\% residing in the cytoplasmic fraction. This contrasts with PDE3, which contributes 69\% of cAMP esterase activity in large mammal cardiac microsomal fractions that include the SR \(^42\). These differences could underlie the lack of PLN phosphorylation and associated SR Ca\(^{2+}\) content.
modulation by PDE1i observed here.

PDE3i or PDE1i increased Ca\textsubscript{v}1.2 current similarly, placing both PDEs within caveolin-enriched microdomains of the sarcolemma, \textsuperscript{43, 44} where this channel resides \textsuperscript{45}. However, the two PDEs displayed marked differences in their interaction with β-AR agonism, with PDE3i augmenting both Ca\textsuperscript{2+} and shortening when combined with Iso but PDE1i having little impact. This suggests that while proximate to the channel, the two PDEs reside in different nanodomains relative to G\textsubscript{s}-coupled GPCRs. Beta-adrenergic stimulated Ca\textsubscript{v}1.2 current requires Rad phosphorylation which otherwise constitutively suppresses current via a complex with the channel’s β and α\textsubscript{1C} subunits \textsuperscript{11, 12}. Proximity protein analysis has identified PDE4 isoforms, PDE3A, and PDE1C as being near Ca\textsubscript{v}1.2. PDE1C is also found in complex with adenosine A\textsubscript{2} receptors and the non-selective cation channel, transient receptor potential cation channel 3 (TRPC3) where it plays a role in cytoprotection signaling\textsuperscript{46}.

**PDE1 and PDE3 differentially impact intracellular PKA signaling**

While our results indicate that β-AR G\textsubscript{s}-coupled cAMP synthesis is regulated by PDE3 rather than PDE1, the sources of cAMP that are more selectively controlled by PDE1 remain to be fully elucidated. As noted, one source may be A\textsubscript{2} adenosine receptors, as A\textsubscript{2B}R blockade \textit{in vivo} prevented positive inotropy in the rabbit \textsuperscript{8}, and PDE1C modulation of A\textsubscript{2}R signaling impacts cAMP-dependent cardioprotection against doxorubicin-mediated cell death \textsuperscript{46}. In the latter case, the Ca\textsuperscript{2+} trigger was coupled to transient receptor potential canonical channel type 3 (TRPC3) identified in a protein
complex with PDE1C and A2R. Interestingly, TRPC3 modulation of myocyte hypertrophy is linked to activation of nuclear factor of activated T-cell (NFAT) that has been shown to require Ca\textsubscript{v}1.2 current as it is suppressed by nifedipine\textsuperscript{47}. This crosstalk works in both directions, as genetic upregulation of TRPC3 slows the decay of the Ca\textsubscript{v}1.2 current, augmenting the net Ca\textsuperscript{2+} transient. The present data showing PDE1 modulation of this channel along with data linking it to TRPC3 suggest that this localized complex likely impacts contractility as well as hypertrophic remodeling.

PDE3i increased arrhythmogenicity more than PDE1i, and importantly this disparity persisted even despite higher levels of basal cAMP stimulation. This resonates with clinical findings, as prior heart failure trials with PDE3i identified malignant arrhythmia as a significant risk\textsuperscript{7}. Sudden cardiac death and increased ventricular ectopy were observed in canine and human HF patients receiving milrinone\textsuperscript{48-50}. In the recently completed clinical trial testing ITI-214 efficacy and tolerance in heart failure patients (NCT03387215), no change in arrhythmias were noted\textsuperscript{10}. These findings are in agreement with results in both rabbit and dog in vivo, where pro-arrhythmia was not detected\textsuperscript{8}, while both studies observed increased contractility and vascular dilation with ITI-214 treatment.

**Limitations**

While this study reveals novel mechanisms for PDE1i inotropy, a number of questions remain to be addressed. The precise localization of the PDE1 regulated cAMP nanodomains, and identity of the proteins directly impacted by its inhibition are
unknown. Studies employing locally targeted fluorescent resonance energy transfer probes and proximity labeling and phospho-proteomics aim to address these unknowns.

Calcium homeostasis is tightly controlled, and while we have shown PDE1i increases Ca\textsubscript{v}1.2 current, this must be balanced by removal via either the SR, the Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger, or mitochondrial Ca\textsuperscript{2+} uniporter\textsuperscript{32}. Whether PDE1i enhances either of the latter two removal mechanisms remains untested, though unlike the SR, they are not thought to be significantly altered by PKA activation\textsuperscript{51} as required for the PDE1i effect. It remains possible that some enhanced SR uptake occurs that is below the detection level of the caffeine release method used here, and we recognize that beyond the patch-clamp studies, direct evidence of a local pool of inward Ca\textsuperscript{2+} with PDE1i in beating cells remains to be obtained. Nanodomain targeted Ca\textsuperscript{2+} sensor studies might address this in future studies. Lastly, while the contraction/calcium responses were PKA dependent and speak to cAMP as the primary modulated species, some role for cGMP remains. PDE1A, which preferentially hydrolyzes cGMP >20x more than cAMP, is also expressed in larger mammals and humans. While very potent, ITI-214 is not PDE1 isoform selective \textsuperscript{52} since the catalytic site is highly homologous among the isoforms. However, cGMP elevation has not been demonstrated to augment Ca\textsubscript{v}1.2, if anything the opposite effect has been reported \textsuperscript{53}.

Conclusions

In summary, we show that similar to PDE3i, PDE1i increases Ca\textsubscript{v}1.2 activity in a PKA-dependent manner, increasing myocyte contraction in cells exposed to
background adenyl cyclase stimulation though not that coupled to β-AR. Unlike PDE3i or β-AR stimulation, PLN, TnI, and MyBP-C are not phosphorylated upon PDE1i. Our findings support PDE1 as a regulator of Ca\textsubscript{v}1.2 that is likely leveraged by the lack of concomitant myofilament Ca\textsuperscript{2+} desensitization, resulting in cAMP/PKA dependent inotropy that is less arrhythmogenic. Ongoing studies at basic and clinical levels will continue to test the potential of this intervention as a heart failure therapy and further clarify its signaling components.
ACKNOWLEDGEMENTS

The authors would like to thank: Dr. Peng Li for providing ITI-214 used in these studies; Drs. Ting Liu and Brian O'Rourke for sharing their expertise in guinea pig handling and myocyte isolation techniques; Dr. Sakthivel Sadayappan for his generous gift of myosin binding protein-C antibodies; Drs. Kobra Haghighi and Litsa Kranias for technical advice on phospholamban western blotting; and Ms. Laurel Keefer for her assistance in R coding language.

SOURCES OF FUNDING

This work was supported by research support from Intracellular Therapies, Inc., Grants AHA 18POST33960157 and 20CDA35260135 to GKM, R35 HL140034 to MEA, and AHA AWRP 17CSA33610107 and NIH/NHLBI R35 HL140034 to DAK.

DISCLOSURES

David Kass is a consultant for Intracellular Therapies, Inc.

Supplemental Materials

Online Figures 1 - 3
REFERENCES


Fig 1. PDE1-I stimulates contraction at less Ca\(^{2+}\) rise than PDE3-I in guinea pig. Myocytes were treated with inhibitors targeting PDEs 1, 3, or 4: ITI-214 (214; 1 µM), cilostamide (Cil; 1 µM), and rolipram (Rol; 10 µM), respectively; or with isoproterenol (Iso; 1 nM). A) Representative traces showing changes in cell sarcomere shortening (upper traces), and Ca\(^{2+}\) transients (lower traces). Peak changes in B) sarcomere shortening and C) Ca\(^{2+}\) transient amplitude are plotted in a paired fashion against
DMSO (open dot). *p<0.05, **p<0.01, ****p<0.0001 against respective DMSO; RM 2-way ANOVA with Sidak’s multiple comparison test. A separate group of cells were treated with forskolin (Fsk; at 10 or 100 nM), with or without additional 214 or Cil. The group averaged delta values for D) sarcomere shortening and E) Ca\(^{2+}\) transients from DMSO are plotted. *p<0.05, **p<0.01, ****p<0.0001 against respective DMSO; Kruskal-Wallis test. F) Change in sarcomere shortening was compared in the absence or presence of 100 µM Rp-8-CPT-cAMPS for cells treated with Fsk (10 nM), Fsk (10 nM) + 214 (1 µM), or Fsk (10 nM) + Cil (1 µM). *p<0.01, **p<0.001 vs corresponding baseline (Bl), †p<0.05 vs corresponding drug condition in the presence of Rp-8-CPT-cAMPS; ordinary 2-way ANOVA with Sidak’s test.
Fig 2. **PDE1-I vs PDE3-I modulation of β-AR-stimulated signaling.** Guinea pig myocytes were treated with sub-maximal isoproterenol (Iso; 0.025 nM) alone, or with Cil or 214. Changes in the peak A) sarcomere shortening and B) Ca\(^{2+}\) transients are plotted, with p-values indicating paired T-test results. The delta differences are plotted to the right. For the delta comparison, p values indicate the results of a Kruskal-Wallis test.
Fig 3. **PDE1 inhibition does not alter the myofilament force-pCa relationship.**

Guinea pig myocytes were treated with DMSO, Fsk (10nM) + 214 (1 µM), or Iso (50 nM) before being skinned. A) A normalized curve showing the myofilament force-pCa relationship. B) The EC50 values, indicative of Ca2+ at 50% maximal activation, are plotted for these groups. C) Representative western blot of phosphorylated and total troponin I (TnI) at Ser23/24 or myosin binding protein-C (MyBP-C) at Ser273, Ser282 and Ser302 for guinea pig myocytes treated as indicated. The averaged group response, normalized to the saturating level of Fsk (25 µM) + IBMX (100 µM), is shown below. *p<0.05, **p<0.01; Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test.
Fig 4. **PDE1 inhibition does not increase the SR Ca^{2+} content, or the phospholamban (PLN) Ser^{16} phosphorylation level.** Guinea pig myocytes treated with DMSO, Fsk (10nM) + 214 (1 µM) or Iso (1 nM) were treated with caffeine (10 mM). A) Representative Ca^{2+} traces are shown. B) Grouped average changes in the peak Ca^{2+} transients and relaxation constant tau are plotted, with p-values indicating Kruskal-
Wallis test results. Representative western blot of phosphorylated (Ser^{16}) and total PLN for myocytes treated with Fsk (10nM) + 214 (1 µM) in comparison to those treated with C) Iso at near maximal dose (50 nM) with quantiation to the right, or E) Iso at non-saturating dose (1 nM). E) Grouped average data are plotted. The level of phosphorylated/total PLN was normalized to that of Fsk+IBMX in D, or to that of DMSO, or Iso+cil or Fsk+cil in F, going from left to right. **** p<0.0001 vs DMSO, † p=0.0005 vs 214 in PDE series; *p<0.05, ** p<0.01, **** p<0.0001 vs Fsk+cil or Iso+cil in the rest; Kruskal-Wallis test.
Fig 5. The L-type Ca$^{2+}$ channel (LTCC) current increases upon PDE1 or 3 inhibition. LTCC current was measured in guinea pig myocytes. Cells were stimulated with the indicated drugs, and the inward current measured using the whole-cell voltage clamp protocol. Nitrendipine (10 µM) was used to confirm LTCC as the primary source of the current. A) The voltage-clamping protocol, and a representative trace showing change upon Fsk+Cil treatment, followed by sensitivity to nitrendipine are shown. B) The averaged peak current density values are plotted over a range of membrane voltage. *p<0.05, $p<0.001, \#p<0.0001$ against DMSO; †p<0.0001 against Fsk+214, ordinary 2-way ANOVA with Tukey’s multiple test. C) Paired-response plotted for change in the peak current density for cells before and after the indicated treatment. ****p<0.0001 vs respective DMSO, RM 2-way ANOVA with Sidak’s multiple test. D) Cells were again stimulated with indicated drugs 8-10 minutes after dialysis with Rp-cAMPS (100 µM). Data points from C are plotted again for comparison without PKA inhibition for change in the peak current density. ****p<0.0001 vs respective drug treatment without Rp-cAMPS; ordinary 2-way ANOVA with Sidak’s multiple test.
Fig 6. The inotropic effects of PDE1 is more sensitive to the LTCC blocker nitrendipine compared to that of PDE3. Cells were pre-treated with nitrendipine (nitr), before being stimulated further with Fsk+214 or Fsk+Cil. Change in sarcomere shortening response at nitr dose of A) 0.01 µM or B) 3 µM are plotted. The fold-difference in C) sarcomere shortening or D) peak Ca\(^{2+}\) transient (e.g., comparing nitr+Fsk+214 or nitr+Fsk+Cil vs DMSO) is plotted against Nitr dose, both expressed on logarithmic scale. The linear fit and 95% CI values are shown. P value in C indicates the difference in the slope, and that in D indicates the difference in the elevation or intercept; simple linear regression.
Fig 7. **PDE1-I is less arrhythmogenic in comparison to PDE3-I.** Guinea pig myocytes treated with 214 or Cil in the presence of Fsk were scored as normal or arrhythmic. A) Representative sarcomere shortening trace for cells responding to 214 (top) or Cil (bottom). Numbers 1-6 indicate regions of interest, with sarcomere shortening traces corresponding to each region shown underneath. Arrows indicate delayed afterdepolarizations (DADs) in cells treated with Cil. B) The percentage of cells in arrhythmic contractions (shades) or normal (white) for indicated conditions.
Fig 8. **Schematic of the proposed working model.** PDE1C may be part of a negative feedback mechanism controlling Ca\(^{2+}\) influx via Ca\(_{v}\)1.2. Downstream of Ca\(_{v}\)1.2 activation by a GPCR, PDE1C senses an increase in LTCC activity putatively via Ca\(^{2+}\)/CaM. PDE1C hydrolyzes cAMP to AMP to relieve the stimulatory effects of PKA upon Ca\(_{v}\)1.2activity. This negative feedback mechanism may operate in conjunction with Ca\(^{2+}\)-induced Ca\(_{v}\)1.2 inactivation. In contrast, PDE3A hydrolyzes a different pool of cAMP at the SR to increase PKA phosphorylation of PLN to release its inhibition of SERCA-mediated Ca\(^{2+}\) reuptake. This likely occurs in conjunction with PKA phosphorylation of PDE3A to directly increase SERCA activity. Abbreviations: G-protein coupled receptor (GPCR), stimulatory G protein (Gs), adenylyl cyclase (AC), phosphodiesterase 1C (PDE1C), phosphodiesterase 3A (PDE3A), protein kinase A (PKA), calmodulin (CaM), sarcoplasmic reticulum (SR), SR Ca\(^{2+}\) ATPase (SERCA), phospholamban (PLN), ryanodine receptor (RyR).
Table 1. Myofilament parameters in skinned guinea pig myocytes

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>Iso</th>
<th>Fsk+214</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fmax</strong></td>
<td>20 ± 1.9</td>
<td>23 ± 3.6</td>
<td>16 ± 2.4</td>
</tr>
<tr>
<td><strong>EC\textsubscript{50}</strong></td>
<td>2.4 ± 0.12</td>
<td>4.6 ± 0.69 *</td>
<td>2.8 ± 0.57</td>
</tr>
<tr>
<td><strong>Hill's coefficient</strong></td>
<td>5.5 ± 1</td>
<td>3.3 ± 0.58</td>
<td>3.9 ± 0.69</td>
</tr>
</tbody>
</table>

* p=0.02 vs DMSO; ordinary 1-way ANOVA with Dunnett's test